2023 Fiscal Year Final Research Report
Developement of TERT-targeting novel therapy of malignant meningioma
| Project/Area Number |
20K09401
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
TAKAHASHI Masamichi 国立研究開発法人国立がん研究センター, 中央病院, 医長 (10436454)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 髄膜腫 / TERT / エリブリン |
|---|
| Outline of Final Research Achievements |
Malignant meningioma is impossible to cure by surgical resection alone, while there are still no effective molecular targetting therapies for this tumor. Recently, we have developed an investigator-initiated clinical trial of eribulin for glioblastoma with TERT mutations. As TERT mutations are highly prevalent in malignant meningiomas, the aim of this study was to analyze the therapeutic efficacy of eribulin in malignant meningiomas and to translate the results into clinical application. The cytotoxicity effect of eribulin on malignant meningioma cell lines was evaluated, and the anti-tumor effect was assessed in mouse tumor models, where eribulin showed effectiveness in tumor growth suppression and prolongation of survival of mouse models. These results suggest that eribulin is a promising agent for the treatment of malignant meningiomas.
|
| Free Research Field |
脳神経外科
|
| Academic Significance and Societal Importance of the Research Achievements |
未だ有効な化学療法、分子標的療法が存在しない悪性髄膜腫に対し、今回の研究ではTERT遺伝子異常によるRdRP活性に着目してエリブリンがこの難治性腫瘍に対する治療薬候補として有望であることを証明した。従来は手術と放射線治療しか治療方法としての選択肢がなかったこの難治性腫瘍に対して、前臨床研究により新規治療法開発の理論的基盤を構築することが出来た意義は大きいと考えられる。今後は、希少疾患である悪性髄膜腫に対して多施設共同臨床試験の実施によりこの薬剤の有効性が検証されることが望まれる。
|
